 Product
Symadex®
Licensee
Xanthus Pharmaceuticals, Inc
Indication
Metastatic breast cancer, multiple sclerosis
Phase
Phase II - Metastatic breast cancer
Preclinical - MS
Description
Potent and selective FLT3 receptor tyrosine kinase inhibitor.
Return to Pipeline
|